BiotechTube

TPO-RA (Herombopag) + TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tumor Therapy-related Thrombocytopenia

Conditions

Tumor Therapy-related Thrombocytopenia

Trial Timeline

Jun 1, 2022 → Oct 30, 2023

NCT ID
NCT05350956

About TPO-RA (Herombopag) + TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)

TPO-RA (Herombopag) + TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin) is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Tumor Therapy-related Thrombocytopenia. The current trial status is unknown. This product is registered under clinical trial identifier NCT05350956. Target conditions include Tumor Therapy-related Thrombocytopenia.

What happened to similar drugs?

20 of 20 similar drugs in Tumor Therapy-related Thrombocytopenia were approved

Approved (20) Terminated (3) Active (0)
✅PexidartinibDaiichi SankyoApproved
✅KRN23Kyowa KirinApproved
✅DurvalumabAstraZenecaApproved
✅aprepitant + Dexamethasone and Ondansetron during CE-treatmentMerckApproved
✅Everolimus (RAD001)NovartisApproved
✅Chromogranin ANovartisApproved
✅Pasireotide + DiazoxideNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05350956Phase 2UNKNOWN

Competing Products

20 competing products in Tumor Therapy-related Thrombocytopenia

See all competitors
ProductCompanyStageHype Score
ALG.APV-527Alligator Bioscience ABPhase 1/2
18
ATOR-1017Alligator Bioscience ABPhase 1
19
ATOR-1015Alligator Bioscience ABPhase 1
19
mRNA-4359ModernaPhase 2
0
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
mRNA-2416ModernaPhase 2
0
E7050EisaiPhase 1
29
FruquintinibHUTCHMEDPhase 1
23
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
BBP-398 + sotorasibBridgeBio PharmaPhase 1
18
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
18
CixutumumabEli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
27
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
27